Radar · Immunology in Massachusetts
Best Immunology Companies in Massachusetts, United States
The 123 best Immunology companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Generate Biomedicines.
By Riya SenguptaFinancials
123companies tracked
$9.4Bdisclosed funding
1unicorns
95have raised
Ranked: Best Immunology companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Generate Biomedicines 🦄 Developer of a platform for generating novel protein-based therapeutic modalities 78AI top 18%Funding top 23%News top 24%Innovation top 25% All 12 signals ▾AItop 18% Fundingtop 23% Newstop 24% Innovationtop 25% Growthtop 25% Patentstop 25% Moattop 25% Talenttop 28% Markettop 45% Techbottom 43% Globalbottom 42% Fin. healthbottom 39% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $643M | 18 mo ago | 75 | Gevorg Grigoryan Co-Founder & CTO | Craft CMSApple iCloud MailPHP+17 | 36 patents Patents concentrated in chemistry & materials | — |
| 2 | Nimbus Therapeutics Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 33 mo ago | 81 81 → 99 (+22%) · sector median +22% | Jeb Keiper CEO | WordPressApple iCloud MailMySQL+14 | — | — |
| 3 | Odyssey Developer of immunotherapeutics for immunological and cancer diseases 74Funding top 12%Growth top 13%Talent top 28%Moat top 31% All 7 signals ▾Fundingtop 12% Growthtop 13% Talenttop 28% Moattop 31% Techbottom 46% Marketbottom 45% Globalbottom 39% Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $503M | 12 mo ago | 108 108 → 118 (+9%) · sector median +22% | Paul-Albert König Co-Founder and Sr. Director Biology | WordPressApple iCloud MailMicrosoft 365+22 | — | — |
| 4 | Upstream Bio Developer of therapeutics for allergic and inflammatory diseases | $400M | 36 mo ago | 33 | Oren Becker Founder | DrupalPHPAmazon Web Services+14 | — | 4 job openings |
| 5 | AvenCell Developer of next-generation switchable CAR T-cell immunotherapies 40Funding top 17%Moat top 42%Talent bottom 49%Market bottom 45% All 6 signals ▾Fundingtop 17% Moattop 42% Talentbottom 49% Marketbottom 45% Globalbottom 45% Techbottom 35% Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $362M | 11 mo ago | 67 | Andrew Schiermeier Chief Executive Officer | WordPressApple iCloud MailMySQL+16 | — | — |
| 6 | Sionna Developer of therapeutics to treat cystic fibrosis | $332M | 27 mo ago | 18 | — | DrupalPHPAmazon Web Services+28 | — | 1 job opening |
| 7 | Abcuro Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer 42Funding top 22%Moat top 28%Growth top 35%Patents top 35% All 9 signals ▾Fundingtop 22% Moattop 28% Growthtop 35% Patentstop 35% Innovationtop 36% Globalbottom 42% Marketbottom 32% Techbottom 19% Newsbottom 17% Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $252M | 16 mo ago | 24 24 → 40 (+67%) · sector median +22% | — | WordPressMySQLPHP+13 | 48 patents Therapeutic anti‑KLRG1 antibodies for treating immune‑cell malignancies and autoimmune diseases | — |
| 8 | Astria Therapeutics Developer of therapeutics for rare diseases | $229M | 64 mo ago | 59 | Jill Milne Founder and CEO | WordPressApple iCloud MailMySQL+20 | — | — |
| 9 | C4 Therapeutics Developer of small molecule drugs for treating cancer | $223M | 29 mo ago | 121 121 → 113 (-7%) · sector median +22% | Marc Cohen Co-Founder | DrupalPHPAmazon Web Services+16 | 1,876 patents Patents concentrated in chemistry & materials | 1 internship |
| 10 | Triveni Bio Developer of functional antibodies for the treatment of immunological and inflammatory disorders | $207M | 20 mo ago | — | Vishal Patel CEO | — | — | — |
| 11 | Third Harmonic Bio Developer therapeutics to treat allergy and inflammatory diseases | $205M | 52 mo ago | 28 | Natalie Holles Chief Executive Officer | WordPressApple iCloud MailMicrosoft 365+17 | — | — |
| 12 | ROME Therapeutics Developer of therapeutics for cancer and autoimmune disorders | $199M | 33 mo ago | 32 | — | — | — | — |
| 13 | Kymeratx Developer of small molecule protein degraders for multiple disorders | $197M | 46 mo ago | 150 150 → 302 (+101%) · sector median +22% | Nello Mainolfi Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+24 | — | 1 launch |
| 14 | Aera Developer of genetic medicines across a wide range of therapeutic areas | $193M | 40 mo ago | 70 | Feng Zhang Founder | — | 2 patents Deployable-wing UAVs and modular aerial vehicle structures for compact storage | — |
| 15 | Repertoire Immune Medicines Developer of T-cell based drugs for the treatment of immune disorders | $189M | 62 mo ago | 46 46 → 84 (+83%) · sector median +22% | — | Craft CMSApple iCloud MailMicrosoft 365+4 | 72 patents Targeted CD8 T‑cell immunotherapy via lipid nanoparticle delivery and cytokine‑fusion proteins | — |
| 16 | Garuda Developer of stem cell-based therapies to treat multiple diseases | $182M | 20 mo ago | 44 | David Scadden Co-Founder | — | 2 patents Patents concentrated in computing, sensing & instrumentation | — |
| 17 | Skyhawk Therapeutics Developer of RNA-modifying drug candidates for the treatment of multiple disorders | $181M | 57 mo ago | 86 | — | WixSentryBootstrap+14 | 229 patents RNA splicing modulators for treating neurodegenerative diseases | 1 launch |
| 18 | Third Arc Bio Developer of therapetics for cancer and immunological diseases 37Funding top 20%Talent top 38%Moat bottom 48%Tech bottom 47% All 7 signals ▾Fundingtop 20% Talenttop 38% Moatbottom 48% Techbottom 47% Globalbottom 36% Marketbottom 32% Newsbottom 18% Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $165M | 4 mo ago | — | Sanjaya Singh Founder & Chief Scientific Officer | GSAPReactGatsby+15 | — | — |
| 19 | Apogee Therapeutics Developer of therapeutics for immunological and inflammatory disorders | $149M | 42 mo ago | 91 | Nimish Shah Co-Founder | DrupalApple iCloud MailMicrosoft 365+24 | — | — |
| 20 | Seres Therapeutics Developer of microbiome therapeutics to treat a wide range of diseases | $134M | 24 mo ago | 332 | David Berry Founder | DrupalApple iCloud MailMicrosoft 365+24 | 274 patents Live bacterial therapeutics for gut microbiome modulation in infection and cancer treatment | — |
| 21 | Morphic Therapeutic Developer of small molecule integrin inhibitors for immunological, fibrotic, neoplastic and vascular diseases | $132M | 39 mo ago | 121 | Praveen Tipirneni CEO | — | 233 patents Therapeutic integrin inhibition and antibody development for disease modulation | — |
| 22 | CREATE Medicines Developer of messenger ribonucleic acid therapies for immune cell programming 50Funding top 20%Patents top 41%Innovation top 47%Talent bottom 49% All 5 signals ▾Fundingtop 20% Patentstop 41% Innovationtop 47% Talentbottom 49% Globalbottom 35% Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $122M | 1 mo ago | — | Daniel Getts Co-Founder & CEO | — | 18 patents Therapeutic chimeric fusion proteins and gene/miRNA delivery platforms for drug development | — |
| 23 | Abata Developer of cell therapies for autoimmune and inflammatory disease | $110M | 22 mo ago | 50 | Samantha Singer President & Chief Executive Officer | — | — | — |
| 24 | Alltrna Developer of tRNA medicines for various therapeutic areas | $109M | 34 mo ago | 46 46 → 48 (+4%) · sector median +22% | Theonie Anastassiadis Co-Founder | — | — | — |
| 25 | Q32 Bio Developer of drugs for treating autoimmune disorders | $106M | 26 mo ago | 34 34 → 29 (-15%) · sector median +22% | Shelia Violette Founder & CSO | DrupalPHPAmazon Web Services+26 | — | — |
| 26 | Mediar Therapeutics Developer of antibody-based therapeutics for treating fibrosis 19Funding top 25%Moat top 48%Talent bottom 49%News bottom 42% All 6 signals ▾Fundingtop 25% Moattop 48% Talentbottom 49% Newsbottom 42% Globalbottom 39% Marketbottom 21% Funding: Raised $105M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $105M | 6 mo ago | 2 | Rahul Ballal CEO | — | — | — |
| 27 | Nocion Therapeutics Developer of therapeutics for the treatment of multiple diseases 42Funding top 23%Talent top 28%Moat top 39%Global bottom 39% All 6 signals ▾Fundingtop 23% Talenttop 28% Moattop 39% Globalbottom 39% Marketbottom 34% Newsbottom 18% Funding: Raised $104M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $104M | 6 mo ago | 15 15 → 19 (+27%) · sector median +22% | Clifford Woolf Co-Founder | — | — | — |
| 28 | Allorion Therapeutics Developer of therapeutics to treat cancer and autoimmune diseases | $100M | 39 mo ago | 16 | Fang Li Co-Founder | — | — | — |
| 29 | Tectonic Therapeutic Developer of GPCR-targeted therapies | $80M | 16 mo ago | 28 28 → 69 (+146%) · sector median +22% | — | DrupalPHPAmazon Web Services+22 | — | — |
| 30 | Zag Bio Developer of thymus-targeted medicines for autoimmune disease treatment and prevention | $80M | 7 mo ago | — | Diane Mathis Co-Founder | — | — | — |
| 31 | Biogen Developer of therapies for neurodegenerative and immunology disorders | $80M | 28 mo ago | 9,482 | Heinz Co-Founder | DrupalAdobe Experience ManagerApple iCloud Mail+25 | 3,803 patents Therapeutic biologics, antibodies, and gene‑therapy vectors for neuro‑immune diseases | — |
| 32 | Cogent Biosciences Developer of precision therapy for genetically defined diseases | $77M | 28 mo ago | 164 164 → 294 (+79%) · sector median +22% | Charles Wilson Founder & CEO | WordPress Block EditorElementorWordPress+23 | 40 patents Small-molecule kinase inhibitors for oncology (PI3K, HER2/ERBB2, JAK2 V617F) | — |
| 33 | DeepCure AI-driven drug discovery platform for inflammation & immunology space | $72M | 26 mo ago | 22 22 → 27 (+23%) · sector median +22% | Kfir Schreiber Co-Founder & CEO | — | 10 patents AI-driven drug discovery and automated chemical synthesis workflow optimization | — |
| 34 | Hillstar Bio Developer of precision immunotherapies for autoimmune diseases | $67M | 14 mo ago | — | Robert Mabry CEO | WordPressApple iCloud MailMySQL+13 | — | — |
| 35 | DeepCure Developer of novel small molecule therapies for immune diseases | $65M | 26 mo ago | — | Thrasyvoulos Karydis Co-Founder & CTO | Cart FunctionalitySquarespace CommerceSquarespace+12 | 10 patents AI-driven drug discovery and automated chemical synthesis workflow optimization | — |
| 36 | Auron Therapeutics Developer of cancer therapeutics for the treatment of blood cancer | $63M | 16 mo ago | 27 | Kate Yen Co-Founder & CEO | WebflowApple iCloud MailZendesk+11 | — | — |
| 37 | Redona Therapeutics Developer of RNA therapeutics to treat cancer and other human diseases | $61M | 34 mo ago | 22 | Richard Gregory Co-Founder | — | — | — |
| 38 | Artax Biopharma Developer of small molecules for the treatment of autoimmune and inflammatory diseases | $51M | 22 mo ago | 2 | — | — | 67 patents Small-molecule chromene inhibitors of TCR‑Nck signaling for immunotherapy enhancement | — |
| 39 | Oncimmune Immunodiagnostics company developing biomarker platforms for cancer and immune diseases | $49M | 19 mo ago | 62 62 → 35 (-44%) · sector median +22% | Jamie Heywood Managing Director | WordPressMySQLPHP+21 | 4 patents Immunoassay development and calibration technologies for diagnostic testing | — |
| 40 | OcuTerra Therapeutics Developer of eye drop to treat diabetic eye disease | $40M | 30 mo ago | 4 | — | — | — | — |
| 41 | Solu Therapeutics Developer of therapeutics for oncology and immunology diseases | $31M | 14 mo ago | 9 | John Pribis Co-founder | WebflowTypekitMicrosoft Advertising+11 | — | — |
| 42 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 1 mo ago | 51 51 → 39 (-24%) · sector median +22% | — | WordPress Block EditorWordPressMySQL+15 | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 43 | Boston Immune Technologies & Therapeutics Developer of immune-based therapies for treating cancer and infectious diseases | $10M | 16 mo ago | 6 | — | — | — | — |
| 44 | Purinomia Biotech Developer of therapies for treating cancer and inflammatory diseases | $8M | 24 mo ago | 8 | Anderson Wang Co-Founder & CEO | — | — | — |
| 45 | Signa Blok Developer of peptide therapeutics targeting receptor signaling 32Funding top 42%Innovation top 43%Product bottom 44%Market bottom 37% All 5 signals ▾Fundingtop 42% Innovationtop 43% Productbottom 44% Marketbottom 37% Globalbottom 29% Funding: Raised $7.3M across 15 rounds · 15 rounds over 14 yrs (1.1/yr) Innovation: 2 product lines rank vs industry peers · Fliar Intelligence Index 32/100 | $7M | 14 mo ago | — | — | — | — | — |
| 46 | Thymmune Developer of immunetherapeutics for immune-disorders | $7M | 13 mo ago | 9 | Stan Wang Founder & CEO | — | — | 2 job openings |
| 47 | Remedium Bio Developer of gene therapies for a broad range of diseases 7Funding top 37%Moat top 48%Global bottom 36%Tech bottom 22% All 5 signals ▾Fundingtop 37% Moattop 48% Globalbottom 36% Techbottom 22% Marketbottom 20% Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 7/100 | $6M | 1 mo ago | 5 | — | Google MapsBootstrapNginx+6 | — | 1 job opening |
| 48 | LAPIX Developer of immunotherapies for immunological diseases | $3M | 11 mo ago | 9 | Anas Fathallah Co-Founder & CEO | WordPressMySQLPHP+16 | — | — |
| 49 | Oasis Pharmaceuticals Developer of therapeutics to treat inflammatory, fibrotic, and metabolic disorders | $2M | 13 mo ago | — | Lidija Covic Founder & CSO | — | — | — |
| 50 | HasenTech Developer of therapies using bacterial sugars to dampen inflammatory responses | $599K | 13 mo ago | — | Richard Goldsby Co-Founder | — | 3 patents Therapeutic dendritic cell immunomodulation to prevent graft‑versus‑host disease | — |
Top 12 Immunology companies in Massachusetts
#1
Series B · Cambridge, Massachusetts · founded 2019$122Mraised▾
Series B · Cambridge, Massachusetts · founded 2019
Developer of messenger ribonucleic acid therapies for immune cell programming. These therapies utilize lipid nanoparticle delivery systems to modify immune cells directly within the body. The technology targets specific cell types to address conditions related to oncology and autoimmunity. The approach focuses on the expression of chimeric antigen receptors to facilitate immune responses against disease targets.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 20%Patents
top 41%Innovation
top 47%Talent
bottom 49%Global
bottom 35%Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (May 2026)
Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Innovation: 18 patents (top 74% of patent-holders) · 17 filings since 2022 vs 1 in 2017-21
Funding rounds
- May 2026Series B$122M
Founders & team
Investors
Newpath Partners, Hatteras Venture Partners, Arch Venture Partners, Alexandria Venture Investments
#2
Series A · Boston, Massachusetts · founded 2022$165Mraised▾
Series A · Boston, Massachusetts · founded 2022
Developer of therapetics for cancer and immunological diseases. It offers multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. It has technology platform a solid tumor synergy platform and an I&I platform fornimmune regulation at a tissue-specific level.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Moat
bottom 48%Tech
bottom 47%Global
bottom 36%Market
bottom 32%Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Feb 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 1/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Adagene) announced in 12 mo
Funding rounds
- Feb 2026Series A$52M
- Jul 2024Series A$165M
Founders & team
Investors
Vida Ventures, Cormorant Asset Management, Hillhouse, Goldman Sachs Asset Management, BVF Partners, Janus Henderson Investors
Tech stack
AosCookieyesCore-JsDocusignGatsbyGodaddy
#3
Public · Cambridge, Massachusetts · founded 2015 · 51 employees$26.4Mraised▾
Public · Cambridge, Massachusetts · founded 2015 · 51 employees
Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Innovation
top 16%Patents
top 16%News
top 28%Moat
top 29%Growth
top 31%Partners
top 32%Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21
Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 · Latest publication 2026
News: 16 BI events in 12 mo (of 40 tracked, 7 types) · +45% YoY · Top themes: Board, Leadership, Earnings
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- May 2026Post IPO$30M
- Nov 2022Post IPO$30M
- Dec 2016Series A$16.4M
- Jun 2015Seed$10M
Investors
MDB Capital
Tech stack
Google AnalyticsGoogle Font ApiJqueryJquery MigrateModernizrMysql
#4
Series B · Waltham, Massachusetts · founded 2017 · 15 employees$104Mraised▾
Series B · Waltham, Massachusetts · founded 2017 · 15 employees
Developer of therapeutics for the treatment of multiple diseases. The company develops small-molecule therapies that selectively target and silence actively firing nociceptors to treat conditions like chronic cough, itch, pain, and inflammation.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 23%Talent
top 28%Moat
top 39%Global
bottom 39%Market
bottom 34%News
bottom 18%Funding: Raised $104M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series B (Dec 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Dec 2025Series B$23M
- Feb 2024Series B$62M
- Jan 2021Series A$15M
- Apr 2019Series A$27M
Founders & team
Investors
Arkin Holdings, Monograph, Canaan, F-Prime Capital, Mass General Brigham, Mission BioCapital
#5
Public · Cambridge, Massachusetts · founded 2018 · 108 employees$503.2Mraised▾
Public · Cambridge, Massachusetts · founded 2018 · 108 employees
Developer of immunotherapeutics for immunological and cancer diseases. It offers anti-inflammation immunotherapies such as anti-TNF antibodies and JAK inhibitors for inflammatory diseases and cancer. It has a computational drug discovery platform.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 12%Growth
top 13%Talent
top 28%Moat
top 31%Tech
bottom 46%Market
bottom 45%Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series D (Jun 2025)
Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 15k LinkedIn followers — 3.9% of this cohort's audience
Funding rounds
- Jun 2025Series D$214M
- Oct 2023Series C$117.2M
- Oct 2022Series B$168M
- Dec 2021Series A$218M
Founders & team
Investors
General Catalyst, Alexandria, Walleye, Catalio Capital Management, GreatPoint Ventures, SVB Securities
Tech stack
Apple Icloud MailCdnjsCloudflareCloudflare Bot ManagementCookieyesCore-Js
#6
Series B · Cambridge, Massachusetts · founded 2018 · 2 employees$105Mraised▾
Series B · Cambridge, Massachusetts · founded 2018 · 2 employees
Developer of antibody-based therapeutics for treating fibrosis. The company has developed therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Funding
top 25%Moat
top 48%Talent
bottom 49%News
bottom 42%Global
bottom 39%Market
bottom 21%Funding: Raised $105M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series B (Dec 2025)
Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Dec 2025Series B$76M
- Nov 2022Series A$105M
- Mar 2021Seed—
Founders & team
Investors
Ono Venture Investment, Pfizer Ventures, Gimv, Pfizer, Mission BioCapital, PureOS
#7
Series B · Watertown, Massachusetts · founded 2021 · 67 employees$362Mraised▾
Series B · Watertown, Massachusetts · founded 2021 · 67 employees
Developer of next-generation switchable CAR T-cell immunotherapies. This company develops allogeneic platforms to address shortcomings of current T cell-based immunotherapies. Their technology offers powerful controllability of CAR-T reactivity while maintaining high anti-tumor activity. A switchable on/off mechanism, using universal effector cells and soluble adaptors, allows precise targeting of cancer antigens. Rapid switchability lowers the risk of side effects, improving the therapeutic window and safety. The focus is on overcoming limitations of current CAR-T cell therapies.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 17%Moat
top 42%Talent
bottom 49%Market
bottom 45%Global
bottom 45%Tech
bottom 35%Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Grant (prize money) (Jul 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Jul 2025Grant (prize money)$40M
- Oct 2024Series B$112M
- Feb 2023Grant (prize money)$284.1K
- Jun 2021Series A$250M
Founders & team
Investors
Novo Holdings, Blackstone, F-Prime Capital, Eight Roads Ventures, Piper Sandler, NYBC Ventures
Tech stack
Apple Icloud MailCookiebotCore-JsElementorFont AwesomeGodaddy
#8
Series A · Cambridge, Massachusetts · founded 2022$80Mraised▾
Series A · Cambridge, Massachusetts · founded 2022
Developer of thymus-targeted medicines for autoimmune disease treatment and prevention. It focuses on restoring central immune tolerance through bifunctional antibodies. These antibodies deliver self-antigens to antigen-presenting cells in the thymus. This process harnesses the body’s natural ability to train immune cells to recognize and tolerate self, thereby halting autoimmune attacks. The pipeline includes a program for Type 1 diabetes. It also includes discovery programs for other autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Oct 2025Series A$80M
Founders & team
Investors
Polaris Partners, T1D Fund, Mission BioCapital, AbbVie, Lightspeed Venture Partners, Sanofi Ventures
#9
Public · Somerville, Massachusetts · founded 2018 · 75 employees$643Mraised▾
Public · Somerville, Massachusetts · founded 2018 · 75 employees
Developer of a platform for generating novel protein-based therapeutic modalities. The platform aims to expand technical possibilities to change how medicines are made. It studies proteins to learn rules by which nature encodes function. The company generates medicines across therapeutic modalities with speed and success.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
AI
top 18%Funding
top 23%News
top 24%Innovation
top 25%Growth
top 25%Patents
top 25%AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC)
Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series C (Dec 2024)
News: 6 BI events in 12 mo (of 13 tracked, 3 types) · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: IPO
Audience (LinkedIn): 58k LinkedIn followers — 14.9% of this cohort's audience
Funding rounds
- Dec 2024Series C—
- Sep 2023Series C$273M
- Nov 2021Series B$370M
- Sep 2020Series A$50M
Founders & team
Investors
Amgen, Mirae Asset Capital, Pictet Group, ADIA, Fidelity Investments, T. Rowe Price
Tech stack
Amazon Web ServicesApple Icloud MailCookiebotCraft CmsGoogle AnalyticsGsap
#10
Series A · Needham, Massachusetts · founded 2020 · 5 employees$5.6Mraised▾
Series A · Needham, Massachusetts · founded 2020 · 5 employees
Developer of gene therapies for a broad range of diseases. The company is developing a pipeline of a broad range of therapies for immune and age-related conditions which includes RMD 1101 for rheumatology, RMD 1202 for endocrinology, RMD 1501 for neurology, and RMD 1201 for Type-1 diabetes.
Fliar Intelligence Index™ 7how this company ranks against its industry peers
Funding
top 37%Moat
top 48%Global
bottom 36%Tech
bottom 22%Market
bottom 20%Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Global: Investors from 2 countries beyond United States
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 7 hiring posts in 12 mo (public) · momentum -2 · hiring: Research Associate, Scientist/Senior Scientist, Molecular Biology
Activity (LinkedIn): 1 partnerships (incl. Lilly) announced in 12 mo
Funding rounds
- May 2026Series A$1.5M
- Sep 2024Seed—
- Aug 2023Grant (prize money)$275K
- Aug 2022Seed$2.3M
Investors
LifeSpan Vision Ventures, Sherwood Ventures, Longevitytech.fund, Primo Medical Group, Angel Star Ventures, APIS Health Angels
#11
Series C · Newton, Massachusetts · founded 2015 · 24 employees$251.8Mraised▾
Series C · Newton, Massachusetts · founded 2015 · 24 employees
Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer. It offers ABC008 an anti-KLRG1 antibody for autoimmune muscle disease inclusion body myositis, T cell large granular lymphocytic leukemia, and mature T cell malignancies, ABC015 is a monoclonal antibody for cancer treatment.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 22%Moat
top 28%Growth
top 35%Patents
top 35%Innovation
top 36%Global
bottom 42%Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) · Last round Series C (Feb 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents · Soonicorn
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Feb 2025Series C$200M
- Aug 2023Series B$199.5M
- Jan 2021Series A$42M
- Aug 2019Grant (prize money)$164.1K
Investors
ShangPharma Innovation, Kaitai Capital Management, Sanofi Ventures, Pontifax, Hongsen Investment, RA Capital Management
Tech stack
Apache Http ServerDocusignGenesis ThemeGodaddyGoogle Font ApiJquery
#12
Series B · Natick, Massachusetts · founded 2021 · 44 employees$181.8Mraised▾
Series B · Natick, Massachusetts · founded 2021 · 44 employees
Developer of stem cell-based therapies to treat multiple diseases. The company has developed stem cell transplants by using targeted antibodies and increasing stem cell numbers by targeting self-renewal pathways. The company's pipeline includes therapeutic indications in hematologic malignancies, sickle cell disease, β-thalassemia, bone marrow failure diseases, and more.
Funding rounds
- Oct 2024Series B$47.7M
- Feb 2023Series B$62.1M
- Sep 2021Series A$72M
Founders & team
Investors
Northpond Ventures, Orbimed, Cormorant Asset Management, Aisling Capital, Sectoral, Partners HealthCare
Funding & investor landscape
$9.4Btotal disclosed funding
97companies funded
308disclosed rounds
3rounds last 90 days
Most active investors
Atlas Venture12 rounds
Notable founders
Daniel Getts
Co-Founder & CEO · CREATE Medicines
Sanjaya Singh
Founder & Chief Scientific Officer · Third Arc Bio
Peter Lebowitz
CEO · Third Arc Bio
Clifford Woolf
Co-Founder · Nocion Therapeutics
Bruce Bean
Co-Founder · Nocion Therapeutics
Paul-Albert König
Co-Founder and Sr. Director Biology · Odyssey
Charlie Koniver
Co-Founder · Odyssey
Rahul Ballal
CEO · Mediar Therapeutics
Andrew Schiermeier
Chief Executive Officer · AvenCell
Diane Mathis
Co-Founder · Zag Bio
Alan Crane
Co-Founder · Zag Bio
Gevorg Grigoryan
Co-Founder & CTO · Generate Biomedicines
Prism market signals · United States · country-scoped Prism corpus, 11,202,533 docs
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN MASSACHUSETTS · Health & Bio
How research on Immunology in Massachusetts is moving
A read on the academic research around Immunology in Massachusetts — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 443 papers.
MGH, MIT, and UMass Chan lead Massachusetts immunology research, predominantly advancing CAR-T and cancer immunotherapy with cautiously optimistic momentum, though concern papers remain a minor thread.
443 papers · stance +0.49 · 31% breakthrough · 17% concern
top institutions
- Massachusetts General Hospital317
- Massachusetts Institute of Technology75
- University of Massachusetts Chan Medical School36
- Massachusetts Eye and Ear Infirmary15
- University of Massachusetts Amherst12
leading researchers
Ryan J. Sullivan · Marcela V. Maus · Griffin Kane · Kelly D. DeMarco · Matthew J. Frigault · Howard L. Kaufman
prism intelligence · tone & topics
96% positive · 1% critical tone
PharmaceuticalsBiotechnologyClinical TrialsMedical ResearchHealthOncology
▲
Breakthroughs125 · 28%
▲ 22%→29% share
▲1.3× share momentum0 median citations87% since 2021mostly methods-led
Chimeric antigen receptor research emerged brand-new with 18 papers, driving breakthroughs segment share from 22% to 29%.
rising sub-themes (early→recent)
- Immune system3→50
- Immunotherapy7→39
- Cancer research4→19
- Antigen1→16
- Tumor microenvironment1→16
Newly emergingChimeric antigen receptor 0→18 · Innate immune system 0→9 · Cytokine 0→7
Landmark Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders · 654 cites
◆
Advancements213 · 48%
▼ 54%→47% share
▼0.9× share momentum0 median citations82% since 2021mostly empirical
Immune system advancements intensified sharply — papers rose from 10 to 68 as segment share shifted to 47%.
rising sub-themes (early→recent)
- Immune system10→68
- Immunotherapy15→59
- Cancer1→19
- Tumor microenvironment6→23
- T cell1→17
Newly emergingInternal medicine 0→13 · Adverse effect 0→11 · Radiation therapy 0→9
Landmark Mechanisms of resistance to immune checkpoint inhibitors · 1,328 cites
▼
Concerns69 · 16%
▼ 17%→16% share
▼0.9× share momentum0 median citations86% since 2021mostly empirical
Immunotherapy concerns are rising fast — papers surged from 2 to 26, with chimeric antigen receptor newly flagged.
rising sub-themes (early→recent)
- Immunotherapy2→26
- Immune system3→16
- Cancer2→10
- Clinical trial1→7
- Immune checkpoint2→7
Newly emergingChimeric antigen receptor 0→7 · Oncology 0→7 · Disease 0→7
Landmark ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells · 3,225 cites
Common questions
How many Immunology companies are there in Massachusetts, United States?
Radar tracks 123 indexable Immunology companies headquartered in Massachusetts, United States that meet our profile-completeness bar.
What is the total funding raised by Immunology companies in Massachusetts, United States?
The Immunology companies in Massachusetts, United States on this list have raised a combined $9.4B in disclosed equity funding across 97 funded companies.
Which is the highest-funded Immunology company in Massachusetts, United States?
Generate Biomedicines is the highest-funded Immunology company in Massachusetts, United States, with $643M in disclosed equity funding.
How many Immunology companies in Massachusetts, United States are funded?
97 of the 123 Immunology companies in Massachusetts, United States on this list have disclosed at least one equity funding round.
How many Immunology unicorns are there in Massachusetts, United States?
1 Immunology company in Massachusetts, United States on this list is valued at $1B or more.
Who are the top investors in Massachusetts, United States Immunology companies?
The most active investors in Massachusetts, United States Immunology companies on this list include HHS, Atlas Venture, RA Capital Management, Flagship Pioneering, Orbimed.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.